Patent 9387169 was granted and assigned to Civitas Therapeutics on July, 2016 by the United States Patent and Trademark Office.
The invention provides stable, spray-dried, particle formulations containing rapamycin, or pharmaceutically acceptable salts of rapamycin, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.